Projekt

A Phase 2, randomized, non-comparative, two-arm open label, multiple-center study of CP-751,871 in combination with Docetaxel/Prednisone in chemotherapy-naive (Arm A) and Docetaxel/Prednisone refractory (Arm B) patients with hormone insensitive prostate cancer

Abgeschlossen · 2006 bis 2009